Dianne M Finkelstein

List of Publications by Year
in descending order

142 papers	14,077 citations	34016 52 h-index	21474 114 g-index
146 all docs	146 docs citations	146 times ranked	15408 citing authors

#	Article	IF	Citations
1	Estimation for an accelerated failure time model with intermediate states as auxiliary information. Lifetime Data Analysis, 2020, 26, 1-20.	0.4	4
2	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	5.1	161
3	Design and analysis of a clinical trial using previous trials as historical control. Clinical Trials, 2019, 16, 531-538.	0.7	11
4	Are rare cancer survivors at elevated risk of subsequent new cancers?. BMC Cancer, 2019, 19, 166.	1.1	5
5	Graphing the Win Ratio and its components over time. Statistics in Medicine, 2019, 38, 53-61.	0.8	23
6	A pilot investigation of an iOS-based app for toilet training children with autism spectrum disorder. Autism, 2019, 23, 359-370.	2.4	14
7	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptorâ€"Positive Breast Cancer. Cancer Discovery, 2018, 8, 336-353.	7.7	32
8	Physical symptoms in long-term survivors of rare cancer. Journal of Cancer Survivorship, 2018, 12, 835-842.	1.5	11
9	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Frontiers in Oncology, 2018, 8, 156.	1.3	26
10	Informatively clustering longitudinal microarrays using binary or survival outcome data. Communications in Statistics Case Studies Data Analysis and Applications, 2018, 4, 18-27.	0.3	0
11	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk â€" Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	3.2	99
12	Physical and psychological health in rare cancer survivors. Journal of Cancer Survivorship, 2017, 11, 158-165.	1.5	16
13	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precision Oncology, 2017, 1, 1-9.	1.5	6
14	Global Rank Tests for Multiple, Possibly Censored, Outcomes. Biometrics, 2016, 72, 926-935.	0.8	36
15	Assessing survival benefit when treatment delays disease progression. Clinical Trials, 2016, 13, 352-357.	0.7	5
16	Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project. American Journal of Gastroenterology, 2016, 111, 285-293.	0.2	24
17	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	1.3	4
18	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	2.2	30

#	Article	IF	Citations
19	A model-informed rank test for right-censored data with intermediate states. Statistics in Medicine, 2015, 34, 1454-1466.	0.8	1
20	Outcome-Driven Cluster Analysis with Application to Microarray Data. PLoS ONE, 2015, 10, e0141874.	1.1	6
21	Clinical Grade â€œSNaPshotâ€•Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	2.7	12
22	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	106
23	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. European Journal of Cancer, 2015, 51, 685-696.	1.3	10
24	Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Research and Treatment, 2015, 149, 255-261.	1.1	21
25	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1902-1909.	0.8	351
26	Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 126-133.	1.1	69
27	Poor Survival for American Indians with Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2014, 151, 265-271.	1.1	19
28	A joint test for progression and survival with intervalâ€•censored data from a cancer clinical trial. Statistics in Medicine, 2014, 33, 1981-1989.	0.8	3
29	A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 601-610.	1.1	45
30	Prospective Validation of <i>HLA-DRB1</i>*<i>07:01</i> Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury. Journal of Clinical Oncology, 2014, 32, 2296-2303.	0.8	69
31	Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Research and Treatment, 2014, 145, 233-243.	1.1	32
32	Breast cancer in China. Lancet Oncology, The, 2014, 15, e279-e289.	5.1	1,168
33	Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.. Journal of Clinical Oncology, 2014, 32, 1020-1020.	0.8	143
34	Late effects in rare cancer registrants.. Journal of Clinical Oncology, 2014, 32, e20577-e20577.	0.8	0
35	Clinical grade Â"SNaPshotÂ" genetic mutation profiling in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, e19571-e19571.	0.8	0
36	Planning cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2013, 14, 391-436.	5.1	394

#	Article	IF	Citations
37	Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?. Breast Cancer Research and Treatment, 2013, 140, 485-494.	1.1	91
38	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 88-96.	5.1	128
39	Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. Journal of the National Cancer Institute, 2013, 105, 1036-1042.	3.0	166
40	Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2â€"ve BC): Analysis of patients in the TEACH trial.. Journal of Clinical Oncology, 2013, 31, 628-628.	0.8	1
41	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. Journal of Clinical Oncology, 2013, 31, TPS662-TPS662.	0.8	0
42	Breast cancer in Brazil: present status and future goals. Lancet Oncology, The, 2012, 13, e95-e102.	5.1	127
43	Intraductal papillary mucinous neoplasms: Does a family history of pancreatic cancer matter?. Pancreatology, 2012, 12, 358-363.	0.5	39
44	Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncology, The, 2012, 13, e335-e343.	5.1	110
45	Lapatinib in HER2+ early breast cancer: Quality of life analysis.. Journal of Clinical Oncology, 2012, 30, 604-604.	0.8	0
46	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. Journal of Clinical Oncology, 2012, 30, TPS670-TPS670.	0.8	0
47	Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. Journal of Clinical Oncology, 2012, 30, 596-596.	0.8	0
48	Clinically Relevant Changes in Family History of Cancer Over Time. JAMA - Journal of the American Medical Association, 2011, 306, 172-8.	3.8	40
49	A test for the relationship between a timeâ€varying marker and both recovery and progression with missing data. Statistics in Medicine, 2011, 30, 718-724.	0.8	3
50	Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research, 2011, 4, 1401-1408.	0.7	53
51	Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment, 2010, 124, 441-451.	1.1	33
52	A Score Test for Association of a Longitudinal Marker and an Event with Missing Data. Biometrics, 2010, 66, 726-732.	0.8	7
53	Identification and Interpretation of Longitudinal Gene Expression Changes in Trauma. PLoS ONE, 2010, 5, e14380.	1.1	13
54	Bcl2 and Human Papilloma Virus 16 as Predictors of Outcome following Concurrent Chemoradiation for Advanced Oropharyngeal Cancer. Clinical Cancer Research, 2010, 16, 2138-2146.	3.2	62

#	ARTICLE	IF	CITATIONS
55	Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer. Cancer Research, 2010, 70, 9319-9328.	0.4	159
56	Bayesian design using adult data to augment pediatric trials. Clinical Trials, 2009, 6, 297-304.	0.7	61
57	Analysis of the relationship between longitudinal gene expressions and ordered categorical event data. Statistics in Medicine, 2009, 28, 2817-2832.	0.8	5
58	Meta-analysis of survey data: application to health services research. Health Services and Outcomes Research Methodology, 2008, 8, 98-114.	0.8	39
59	Analysis of familial aggregation studies with complex ascertainment schemes. Statistics in Medicine, 2008, 27, 5076-5092.	0.8	17
60	Common Familial Colorectal Cancer Linked to Chromosome 7q31: A Genome-Wide Analysis. Cancer Research, 2008, 68, 8993-8997.	0.4	34
61	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. JAMA - Journal of the American Medical Association, 2008, 299, 53-60.	3.8	183
62	Increased Prevalence of *EGFR*-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms. Clinical Cancer Research, 2008, 14, 4079-4084.	3.2	71
63	Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 461-469.	2.2	49
64	Validity of Models for Predicting BRCA1 and BRCA2 Mutations. Annals of Internal Medicine, 2007, 147, 441.	2.0	106
65	Regression analysis of failure time data with informative interval censoring. Statistics in Medicine, 2007, 26, 2533-2546.	0.8	46
66	Multivariate logistic regression for familial aggregation in age at disease onset. Lifetime Data Analysis, 2007, 13, 191-209.	0.4	3
67	Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2006, 24, 2897-2902.	0.8	487
68	Analysis of Co-Aggregation of Cancer Based on Registry Data. Public Health Genomics, 2006, 9, 87-92.	0.6	3
69	Survival analysis of longitudinal microarrays. Bioinformatics, 2006, 22, 2643-2649.	1.8	8
70	Data Monitoring in the AIDS Clinical Trials Group Study #981: Conflicting Interim Results. , 2006, , 109-117.		0
71	Analysis of familial aggregation in the presence of varying family sizes. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 847-862.	0.5	5
72	Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer, 2005, 104, 1418-1427.	2.0	14

#	Article	IF	Citations
73	Brain Tumor Oncolysis with Replication-Conditional Herpes Simplex Virus Type 1 Expressing the Prodrug-Activating Genes, CYP2B1 and Secreted Human Intestinal Carboxylesterase, in Combination with Cyclophosphamide and Irinotecan. Cancer Research, 2005, 65, 6850-6857.	0.4	99
74	Prognosis and management of extramammary paget's disease and the association with secondary malignancies. Journal of the American College of Surgeons, 2003, 196, 45-50.	0.2	145
75	Modelling the relationship between continuous covariates and clinical events using isotonic regression. Statistics in Medicine, 2003, 22, 3151-3159.	0.8	6
76	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	13.9	719
77	Comparing Survival of a Sample to That of a Standard Population. Journal of the National Cancer Institute, 2003, 95, 1434-1439.	3.0	129
78	The Cancer Genetics Network: Recruitment Results and Pilot Studies. Public Health Genomics, 2003, 6, 171-177.	0.6	51
79	Efficacy of Trimethoprim–Sulfamethoxazole for the Prevention of Bacterial Infections in a Randomized Prophylaxis Trial of Patients with Advanced HIV Infection. AIDS Research and Human Retroviruses, 2002, 18, 89-94.	0.5	42
80	Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 283-286.	0.6	83
81	Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas. Journal of Clinical Oncology, 2002, 20, 1063-1068.	0.8	257
82	Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer, 2002, 94, 305-313.	2.0	26
83	Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Statistics in Medicine, 2002, 21, 3897-3911.	0.8	54
84	Testing for Dependence Between Failure Time and Visit Compliance with Interval-Censored Data. Biometrics, 2002, 58, 58-63.	0.8	18
85	Analysis of Failure Time Data with Dependent Interval Censoring. Biometrics, 2002, 58, 298-304.	0.8	57
86	Comparing treatment strategies using a synthesized clinical trial: an analysis of late versus early use of trimethoprim-sulfamethoxazole for AIDS patients. Journal of Statistical Planning and Inference, 2001, 96, 179-189.	0.4	0
87	Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer, 2001, 91, 874-880.	2.0	61
88	Fine-needle aspiration cytology of the breast: Invasive vs. in situ carcinoma. Diagnostic Cytopathology, 2001, 25, 73-77.	0.5	42
89	A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l. Aids, 2001, 15, 1509-1515.	1.0	25
90	Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer, 2000, 89, 363-368.	2.0	133

#	Article	IF	Citations
91	Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-Rank Tests. Biometrics, 2000, 56, 779-788.	0.8	589
92	A Proportional Hazards Model for Multivariate Interval-Censored Failure Time Data. Biometrics, 2000, 56, 940-943.	0.8	82
93	Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma. Archives of Dermatology, 2000, 136, 1118-22.	1.7	73
94	Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancerâ€"results from a pilot study. Urology, 2000, 55, 635-638.	0.5	33
95	Applying the Cox Proportional Hazards Model When the Change Time of a Binary Time-Varying Covariate Is Interval Censored. Biometrics, 1999, 55, 445-451.	0.8	31
96	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	15.2	309
97	Combining mortality and longitudinal measures in clinical trials. , 1999, 18, 1341-1354.		225
98	Applying the Cox proportional hazards model for analysis of latency data with interval censoring. , 1999, 18, 2737-2747.		19
99	A non-parametric maximum likelihood estimator for bivariate interval censored data. , 1999, 18, 3089-3100.		52
100	An extension of Kendall's coefficient of concordance to bivariate interval censored data. , 1999, 18, 3101-3109.		21
101	An extension of Kendall's coefficient of concordance to bivariate interval censored data. , 1999, 18, 3101.		1
102	Prognosis and Survival in Patients With Gastrointestinal Tract Carcinoid Tumors. Annals of Surgery, 1999, 229, 815.	2.1	234
103	A Markov Chain Monte Carlo EM Algorithm for Analyzing Interval-Censored Data under the Cox Proportional Hazards Model. Biometrics, 1998, 54, 1498.	0.8	53
104	Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer. New England Journal of Medicine, 1997, 336, 1416-1422.	13.9	197
105	Parental involvement in diabetes management tasks: Relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulin-dependent diabetes mellitus. Journal of Pediatrics, 1997, 130, 257-265.	0.9	477
106	Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genetics, 1997, 15, 307-310.	9.4	329
107	2066 Radiation tolerance of the cervical spinal cord: Incidence and dose-volume relationship of symptomatic and asymptomatic late effects following high dose irradiation of paraspinal tumors. International Journal of Radiation Oncology Biology Physics, 1997, 39, 273.	0.4	9
108	High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. , 1997, 79, 1203-1210.		205

#	Article	IF	Citations
109	ANALYSIS OF MULTIPLE FAILURE TIME DATA FROM AN AIDS CLINICAL TRIAL. Statistics in Medicine, 1997, 16, 951-961.	0.8	17
110	Adjuvant Chemotherapy in Advanced Head and Neck Cancer. Oncologist, 1997, 2, 135-141.	1.9	3
111	Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer. New England Journal of Medicine, 1996, 334, 143-149.	13.9	408
112	Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas. Journal of Neurosurgery, 1996, 85, 602-607.	0.9	118
113	A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 693-699.	13.9	341
114	Blood glucose estimation and symptoms during hyperglycemia and hypoglycemia in patients with insulin-dependent diabetes mellitus. American Journal of Medicine, 1995, 98, 22-31.	0.6	64
115	Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemia. American Journal of Medicine, 1995, 98, 135-144.	0.6	113
116	A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 700-705.	13.9	333
117	Analysing survival in the presence of an auxiliary variable. Statistics in Medicine, 1994, 13, 1747-1754.	0.8	51
118	A Controlled Trial of Trimethoprimâ€"Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1992, 327, 1842-1848.	13.9	365
119	Statistical Issues Arising in AIDS Clinical Trials. Journal of the American Statistical Association, 1992, 87, 562-569.	1.8	34
120	Statistical Issues Arising in AIDS Clinical Trials: Rejoinder. Journal of the American Statistical Association, 1992, 87, 581.	1.8	0
121	Immediate reproducibility of electrically induced sustained monomorphic ventricular tachycardia before and during antiarrhythmic therapy. Journal of the American College of Cardiology, 1991, 17, 133-138.	1.2	29
122	Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: Potentiation by aspirin and reversal with aprotinin. Journal of the American College of Cardiology, 1991, 17, 1213-1222.	1.2	26
123	Delayed Central Nervous System Myelination in the Sudden Infant Death Syndrome. Journal of Neuropathology and Experimental Neurology, 1991, 50, 29-48.	0.9	109
124	Issues in the design of drug trials for AIDS. Contemporary Clinical Trials, 1990, 11, 80-87.	2.0	17
125	Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer. Investigational New Drugs, 1990, 8, 183-5.	1.2	5
126	Design Considerations for AIDS Trials. New England Journal of Medicine, 1990, 323, 1343-1348.	13.9	149

#	Article	IF	Citations
127	Quantitation of acute myocardial infarct size by nuclear magnetic resonance imaging. Journal of the American College of Cardiology, 1990, 15, 143-149.	1.2	44
128	Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. American Journal of Cardiology, 1989, 64, 33-36.	0.7	49
129	Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern cooperative oncology group study. Medical and Pediatric Oncology, 1989, 17, 197-201.	1.0	17
130	Job stress and satisfaction among the staff members at a cancer center. Cancer, 1989, 64, 975-982.	2.0	25
131	Early assessment of the effect of map-guided transcatheter intracardiac electric shock on sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology, 1988, 61, 1018-1023.	0.7	27
132	Predictors of automatic implantable cardioverter defibrillator discharge for life-threatening ventricular arrhythmias. American Journal of Cardiology, 1988, 62, 83-87.	0.7	27
133	Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: Correlation with acute angiography. Journal of the American College of Cardiology, 1988, 11, 729-734.	1.2	93
134	Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: A comparison with cardiac catheterization. Journal of the American College of Cardiology, 1988, 12, 25-34.	1.2	182
135	Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 1988, 318, 19-24.	13.9	475
136	A Pilot Study of the Functional Living Index-Cancer (FLIC) Scale for the Assessment of Quality of Life for Metastatic Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 1988, 11, 630-633.	0.6	99
137	Estimating Carcinogenic Potency from a Rodent Tumorigenicity Experiment. Journal of the Royal Statistical Society Series C: Applied Statistics, 1987, 36, 121.	0.5	19
138	Prognostic Importance of Thallium Uptake by the Lungs during Exercise in Coronary Artery Disease. New England Journal of Medicine, 1987, 317, 1485-1489.	13.9	256
139	Myocardial uptake and clearance of thallium-201 in normal subjects: Comparison of dipyridamole-induced hyperemia with exercise stress. Journal of the American College of Cardiology, 1987, 10, 547-556.	1.2	24
140	A Proportional Hazards Model for Interval-Censored Failure Time Data. Biometrics, 1986, 42, 845.	0.8	531
141	Isotontic regression for interval censored survival data using an e-m algorithm. Communications in Statistics - Theory and Methods, 1986, 15, 2493-2505.	0.6	14
142	Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation. Statistics in Medicine, 0, , .	0.8	0